Last reviewed · How we verify
NCT03389048
Performance Assessment Of The PMD-200 In Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure
NA trial testing PMD-200 in Degenerative Diseases, Nervous System in 21 participants. Terminated before completion.
30 November 2019
Quick facts
| Lead sponsor | Medasense Biometrics Ltd |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 21 |
| Start date | 8 March 2018 |
| Primary completion | 30 November 2019 |
| Estimated completion | 30 November 2019 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- PMD-200
- SLR
Conditions studied
- Degenerative Diseases, Nervous System — all drugs for Degenerative Diseases, Nervous System →
Sponsor
Medasense Biometrics Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Degenerative Diseases, Nervous System. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Performance assessment of the PMD-200, a novel pain monitor, in subjects with degenerative lumbar spine disease who requires surgical procedure
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03389048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PMD-200
Trials testing the same drug.
- NCT03970291 — Impact of NOL Intraoperative Guided Fentanyl Analgesia vs SCC for Elective Major Abdominal Surgery · NA · completed
- NCT03452163 — Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit · NA · terminated
- NCT03276260 — Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care · terminated
- NCT03466138 — Performance Assessment of the PMD-200 in Subjects Requiring Surgery Under General Anesthesia · completed
Other Medasense Biometrics Ltd trials
Trials by the same sponsor.
- NCT04305015 — Postoperative Benefits of Intraoperative Nociception Level (NOL) Titration - Pilot · NA · completed
- NCT04581642 — Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report · completed
- NCT03970291 — Impact of NOL Intraoperative Guided Fentanyl Analgesia vs SCC for Elective Major Abdominal Surgery · NA · completed
- NCT03452163 — Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit · NA · terminated
- NCT03276260 — Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03389048 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medasense Biometrics Ltd
- Last refreshed: 6 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03389048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing